文献速递皮肤肿瘤

巨大戟醇甲基丁烯酸酯减少皮肤癌化区p53阳性角质形成细胞并与临床应答直接相关

Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-27

该研究纳入10例多发性光线性角化病患者,使用巨大戟醇甲基丁烯酸酯凝胶(150和500 mcg/g)治疗,于2和6个月评估。多数患者(7例)出现临床应答,其中6例AK减少、1例完全清除。治疗后2个月癌化区p53阳性角质形成细胞减少程度与AK数量强相关(R2=0.81),提示其减少可能直接参与长期AK减少。

要点

  • 未治疗癌化区p53阳性角质形成细胞水平高,与侵袭性SCC相似。
  • 巨大戟醇甲基丁烯酸酯可减少p53阳性角质形成细胞,但疗效存在个体差异。
  • p53阳性角质形成细胞减少程度与AK数量变化直接相关(R2=0.81)。

核心结论

  • 未治疗皮肤癌化区表达高水平p53阳性角质形成细胞,与侵袭性SCC相似。
  • 巨大戟醇甲基丁烯酸酯能减少p53阳性角质形成细胞,疗效因人而异,减少程度与临床疗效直接相关。

研究设计与样本

  • 纳入n=10例面部/头皮或躯干/四肢多发性AK患者,使用巨大戟醇甲基丁烯酸酯凝胶(150和500 mcg/g)治疗,于治疗后2和6个月评估。

主要发现

  • 多数患者(n=7)出现临床应答,其中AK减少n=6、完全清除n=1;2例无应答,1例初始部分应答后出现新皮损。
  • 未治疗癌化区样本(n=3)中p53阳性角质形成细胞数量为53.56 ± 8.79,侵袭性SCC样本为74.34 ± 22.05(P = 0.2)。
  • 治疗后2个月癌化区p53阳性角质形成细胞减少至24.67 ± 31.19(P = 0.19)。
  • p53阳性角质形成细胞数量与AK数量强且直接相关(R2 = 0.81)。

临床怎么用

  • 巨大戟醇甲基丁烯酸酯治疗多发性AK时,癌化区p53阳性角质形成细胞减少程度或可反映临床应答。

局限性

  • 样本量小(n=10),未治疗癌化区样本仅n=3,p53阳性细胞减少的P值为0.19未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: UV radiation represents the main risk factor for non-melanoma skin cancers. Chronic UV exposure induces 'p53 patches', i.e. clonal outgrowths of keratinocytes with high nuclear expression of mutated p53, which might progress to actinic keratosis (AK) and ultimately squamous cell carcinomas (SCCs). AIMS: Analysis of ingenol mebutate gel (150 and 500 mcg/g) effects in the reduction in 'p53 patches' inside skin cancerization field (CF) in patients with multiple AKs of face/scalp or trunk/extremities, in order to investigate whether the expected reduction in p53+ keratinocytes might have a direct role in the long-term AK reduction in treated areas. RESULTS: We enrolled n = 10 patients, treated with ingenol mebutate and evaluated at 2 and 6 months after treatment. We observed clinical responses in the majority of patients (n = 7), with AK reduction or complete clearance (n = 6 and n = 1, respectively). Notably, two patients did not respond to the treatment, and in one patient, after initial partial response, new lesion was recorded. In untreated skin CF samples (n = 3), we observed numerous p53+ keratinocytes, similar to those observed in invasive SCC samples (53.56 ± 8.79 and 74.34 ± 22.05, respectively; P = 0.2). After treatment, we observed a variable p53+ keratinocyte reduction in CF samples at 2 months (24.67 ± 31.19; P = 0.19). Importantly, the amount of p53+ keratinocytes strongly and directly correlated with AK number (R2 = 0.81). CONCLUSION: Untreated skin CF expresses high level of p53+ keratinocytes as invasive SCC. Ingenol mebutate is able to reduce p53+ keratinocytes with variable efficacy, this reduction degree directly correlating with clinical efficacy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Grandi V, di Gennaro P, Torrigiani S, et al. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses. J Eur Acad Dermatol Venereol. 2019. PMID: 30801837. doi:10.1111/jdv.15528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。